Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.48 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.48 |
| ▸ | PSEN1 | P49768 | 18/20 | 0.42 |
| ▸ | PSEN2 | P49810 | 17/20 | 0.42 |
| ▸ | APH1B | Q8WW43 | 17/20 | 0.42 |
| ▸ | NCSTN | Q92542 | 17/20 | 0.42 |
| ▸ | APH1A | Q96BI3 | 17/20 | 0.42 |
| ▸ | PSENEN | Q9NZ42 | 17/20 | 0.42 |
| ▸ | USP30 | Q70CQ3 | 1/20 | 0.41 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.40 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30668617 | 1.00 | ALDH1A1 (0.48) | ALDH1A1SMN1; SMN2PSEN1PSEN2APH1B | |
| SCHEMBL8032866 | 0.85 | ALDH1A3 (0.50) | ALDH1A1PSEN1PSEN2APH1BNCSTN | |
| SCHEMBL27381057 | 0.82 | ALDH1A1 (0.48) | ALDH1A1SMN1; SMN2PSEN1PSEN2APH1B | |
| SCHEMBL38651491 | 0.82 | ALDH1A1 (0.48) | ALDH1A1SMN1; SMN2PSEN1PSEN2APH1B | |
| SCHEMBL8060709 | 0.82 | KDM4E (0.43) | ALDH1A1PSEN1PSEN2APH1BNCSTN | |
| SCHEMBL1237624 | 0.81 | PSEN1 (0.48) | ALDH1A1SMN1; SMN2PSEN1PSEN2APH1B | |
| SCHEMBL1237622 | 0.81 | PSEN1 (0.48) | ALDH1A1SMN1; SMN2PSEN1PSEN2APH1B | |
| SCHEMBL758550 | 0.80 | PSEN1 (0.57) | ALDH1A1PSEN1PSEN2APH1BNCSTN | |
| SCHEMBL29940580 | 0.80 | PSEN1 (0.57) | ALDH1A1PSEN1PSEN2APH1BNCSTN | |
| SCHEMBL6127819 | 0.80 | PSEN1 (0.43) | PSEN1PSEN2APH1BNCSTNAPH1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 43 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12637426-B2 | 1-cyano-pyrrolidine compounds as USP30 inhibitors | MISSION THERAPEUTICS LIMITED (GB) | 2026-05-26 | — | — | US | disclosed |
| CN-112707893-B | 1-cyanopyrrolidine compounds as USP30 inhibitors | 特殊治疗有限公司 | 2023-10-31 | — | — | CN | disclosed |
| US-20220251041-A1 | 1-CYANO-PYRROLIDINE COMPOUNDS AS USP30 INHIBITORS | MISSION THERAPEUTICS LTD (GB) | 2022-08-11 | — | — | US | disclosed |
| US-11390584-B2 | 1-cyano-pyrrolidine compounds as USP30 inhibitors | MISSION THERAPEUTICS LIMITED (GB) | 2022-07-19 | — | — | US | disclosed |
| EP-3943490-A1 | 1-CYANO-PYRROLIDINE COMPOUNDS AS USP30 INHIBITORS | Mission Therapeutics Limited (GB) | 2022-01-26 | — | — | EP | disclosed |
| EP-3943490-A1 | 1-CYANO-PYRROLIDINE COMPOUNDS AS USP30 INHIBITORS | Mission Therapeutics Limited (GB) | 2022-01-26 | — | — | EP | disclosed |
| US-11066365-B2 | 1-cyano-pyrrolidine compounds as USP30 inhibitors | MISSION THERAPEUTICS LIMITED (GB) | 2021-07-20 | — | — | US | disclosed |
| US-11066365-B2 | 1-cyano-pyrrolidine compounds as USP30 inhibitors | MISSION THERAPEUTICS LIMITED (GB) | 2021-07-20 | — | — | US | disclosed |
| EP-3277677-B9 | 1-CYANO-PYRROLIDINE COMPOUNDS AS USP30 INHIBITORS | MISSION THERAPEUTICS LTD (GB) | 2021-07-14 | — | — | EP | disclosed |
| EP-3277677-B9 | 1-CYANO-PYRROLIDINE COMPOUNDS AS USP30 INHIBITORS | MISSION THERAPEUTICS LTD (GB) | 2021-07-14 | — | — | EP | disclosed |
| EP-3277677-A1 | 1-CYANO-PYRROLIDINE COMPOUNDS AS USP30 INHIBITORS | Mission Therapeutics Limited (GB) | 2018-02-07 | — | — | EP | disclosed |
| WO-2016156816-A1 | 1-CYANO-PYRROLIDINE COMPOUNDS AS USP30 INHIBITORS | MISSION THERAPEUTICS LIMITED (GB) | 2016-10-06 | — | — | WO | disclosed |
| WO-2016156816-A1 | 1-CYANO-PYRROLIDINE COMPOUNDS AS USP30 INHIBITORS | MISSION THERAPEUTICS LIMITED (GB) | 2016-10-06 | — | — | WO | disclosed |
| US-20120053165-A1 | Novel Phenyl Imidazoles and Phenyl Triazoles As Gamma-Secretase Modulators | PFIZER INC. (US) | 2012-03-01 | — | — | US | disclosed |
| US-7737141-B2 | such as -{4-{1-[(S)-1-(4-fluorophenyl)ethyl]-2-oxopiperidin-(3E)-ylidenemethyl}-2-methoxyphenyl}-5-methyl-1-(phosphonooxymethyl)-3H-imidazol-1-ium trifluoroacetate, which inhibit the synthesis of amyloid precursor proteins; treatment of Alzheimer's disease, Down syndrome or amyloidosis | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2010-06-15 | — | — | US | disclosed |
| US-7618960-B2 | Morpholine type cinnamide compound | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2009-11-17 | — | — | US | disclosed |
| EP-2048143-A1 | PRODRUG OF CINNAMIDE COMPOUND | Eisai R&D Management Co., Ltd. (JP) | 2009-04-15 | — | — | EP | disclosed |
| US-20090048213-A1 | Prodrug of cinnamide compound | EISAI R&D MANAGEMENT CO., LTD. | 2009-02-19 | — | — | US | disclosed |
| EP-1953154-A1 | MORPHOLINE TYPE CINNAMIDE COMPOUND | Eisai R&D Management Co., Ltd. (JP) | 2008-08-06 | — | — | EP | disclosed |
| US-20070117798-A1 | Morpholine type cinnamide compound | EISAI R&D MANAGEMENT CO., LTD. | 2007-05-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11066365-B2 | 1-cyano-pyrrolidine compounds as USP30 inhibitors | USP30, USP20, USP10 | ALDH1A1 1172/4885SMN1; SMN2 3214/4885PSEN1 2218/4885 |
| US-20120053165-A1 | Novel Phenyl Imidazoles and Phenyl Triazoles As Gamma-Secretase Modulators | BACE1, BACE2, PSEN1 | ALDH1A1 1903/4885SMN1; SMN2 1918/4885PSEN1 3/4885 |
| US-20220251041-A1 | 1-CYANO-PYRROLIDINE COMPOUNDS AS USP30 INHIBITORS | USP30, USP20, USP10 | ALDH1A1 1264/4885SMN1; SMN2 3078/4885PSEN1 2408/4885 |
| US-20070117798-A1 | Morpholine type cinnamide compound | MLX, XDH, NOX4 | ALDH1A1 785/4885SMN1; SMN2 642/4885PSEN1 3103/4885 |
| US-20090048213-A1 | Prodrug of cinnamide compound | BTK, CNKSR1, AKT1 | ALDH1A1 674/4885SMN1; SMN2 3842/4885PSEN1 2883/4885 |
| US-12637426-B2 | 1-cyano-pyrrolidine compounds as USP30 inhibitors | USP30, USP1, USP10 | ALDH1A1 1185/4885SMN1; SMN2 2487/4885PSEN1 1526/4885 |
| US-11390584-B2 | 1-cyano-pyrrolidine compounds as USP30 inhibitors | USP30, USP20, USP10 | ALDH1A1 1220/4885SMN1; SMN2 3239/4885PSEN1 2399/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.